STOCKHOLM, SWEDEN - Karolinska Development AB (Nasdaq Stockholm: KDEV) has announced that its portfolio company, Umecrine Cognition, has resumed patient inclusion in its Phase 1b/2a clinical study. The study evaluates the efficacy of golexanolone, a drug candidate aimed at alleviating cognitive symptoms in patients with primary biliary cholangitis (PBC). The trial's temporary halt in March was due to technical issues in capsule production, which did not compromise patient safety.

Umecrine Cognition is at the forefront of developing innovative treatments for cognitive symptoms associated with liver diseases. Golexanolone, the company's leading drug candidate, is undergoing a rigorous randomized, double-blind, placebo-controlled study to assess its effectiveness in PBC patients suffering from significant fatigue and cognitive impairments. This development marks a critical step forward in addressing unmet medical needs in liver disease management.

Karolinska Development, holding a 73% stake in Umecrine Cognition, plays a pivotal role in nurturing Nordic life sciences innovations. The investment firm specializes in identifying and growing companies that translate breakthrough medical research into commercial products, offering both therapeutic benefits to patients and attractive returns to investors. The resumption of the clinical trial underscores the resilience and commitment of both companies to advancing healthcare solutions.

The collaboration between Karolinska Development and Umecrine Cognition exemplifies the potential of strategic investments in the life sciences sector. By leveraging world-class medical innovations and expertise, the partnership aims to bring forth treatments that could significantly improve the quality of life for patients with liver diseases. As the clinical trial progresses, the medical community eagerly anticipates the outcomes that could herald a new era in the treatment of cognitive symptoms related to liver conditions.

Autoliv, Inc., the global leader in automotive safety systems, has announced the retirement of 510,361 shares of common stock that were repurchased during the quarter. This move has led to a decrease in the total number of issued shares, now standing at 79,404,229, with 76,807,215 shares outstanding. Each outstanding share retains its entitlement to one vote, underscoring the company's commitment to maintaining a transparent and equitable shareholder structure.

The retirement of these shares has also adjusted Autoliv's treasury stock holdings to 2,597,014 shares. Under Delaware law, these treasury shares do not carry voting rights or rights to participate in distributions. This strategic financial management reflects Autoliv's ongoing efforts to optimize its capital structure and enhance shareholder value, in line with its broader corporate objectives.

This disclosure by Autoliv is in compliance with the Swedish Financial Instruments Trading Act, highlighting the company's adherence to regulatory requirements and its dedication to transparency. The information was made public on June 30, 2025, at 08:00 CET, through the designated contact persons, ensuring timely and accurate communication to the market and its stakeholders.

Autoliv's role as a pioneer in automotive safety systems is well-documented, with its products saving approximately 37,000 lives and reducing around 600,000 injuries in 2024 alone. With operations in 25 countries and a workforce of 65,000 employees, the company continues to drive innovation in mobility safety solutions. The retirement of repurchased shares is a testament to Autoliv's strategic financial planning and its unwavering focus on delivering value to its shareholders while advancing its mission of Saving More Lives.